Market Summary
USD8.81+0.08
Market Closedas of 23 Mar 2023, 09:54 am0.92%
TEVA Stock Price
TEVA RSI Chart
TEVA Valuation
TEVA Price/Sales (Trailing)
TEVA Profitability
TEVA Fundamentals
TEVA Revenue
TEVA Earnings
Price Action
52 Week Range
6.7811.45
(Low)(High)
Last 7 days
-10.2%
Last 30 days
-15.8%
Last 90 days
-3.2%
Trailing 12 Months
15.6%
TEVA Financial Health
TEVA Investor Care
Peers (Alternatives to Teva Pharmaceutical Industries)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
JNJ | 404.8B | 94.9B | -5.16% | -10.64% | 22.56 | 4.26 | 1.25% | -14.07% |
LLY | 296.8B | 28.5B | -5.67% | 20.74% | 47.53 | 10.4 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -1.75% | 40.02% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.4B | 100.3B | -8.43% | -20.95% | 7.22 | 2.26 | 23.43% | 42.74% |
BMY | 142.7B | 46.2B | -7.78% | -1.12% | 22.55 | 3.09 | -0.49% | -9.54% |
| MID-CAP | ||||||||
PRGO | 4.8B | 4.5B | -0.20% | -5.41% | -34.17 | 1.08 | 7.56% | -104.06% |
RETA | 3.3B | 2.2M | 105.10% | 171.03% | -10.52 | 1.5K | -80.71% | -4.88% |
| SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -9.96% | 17.66% | 31.57 | 2.87 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -17.77% | -52.80% | -2.74 | 2.63 | 18.18% | -18.59% |
CGC | 991.7M | 478.9M | -11.35% | -65.42% | -0.32 | 2.07 | -31.50% | -634.70% |
INVA | 792.9M | 285.2M | -7.22% | -37.95% | 3.6 | 2.78 | -27.21% | -40.28% |
CRON | 768.8M | 114.5M | -15.28% | -37.42% | -4.56 | 6.72 | 27.90% | 57.40% |
ACRS | 541.5M | 29.8M | -40.95% | -47.43% | -6.23 | 18.2 | 340.05% | 4.35% |
OCUL | 400.7M | 51.5M | -2.49% | -0.39% | -5.64 | 7.78 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Financials for Teva Pharmaceutical Industries
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | -1.4% | 14,925,000,000 | 15,142,000,000 | 15,434,000,000 | 15,558,000,000 | 15,878,000,000 |
| Gross Profit | -3.9% | 6,973,000,000 | 7,253,000,000 | 7,378,000,000 | 7,457,000,000 | 7,594,000,000 |
| S&GA Expenses | -3.5% | 2,265,000,000 | 2,348,000,000 | 2,406,000,000 | 2,427,000,000 | 2,429,000,000 |
| EBITDA | -36.2% | -809,000,000 | -594,000,000 | 1,712,000,000 | 2,879,000,000 | - |
| EBITDA Margin | -40.8% | -0.05 | -0.04 | 0.11 | 0.18 | - |
| Earnings Before Taxes | -43.2% | -3,065,000,000 | -2,140,000,000 | -1,924,000,000 | -456,000,000 | 658,000,000 |
| EBT Margin | -45.3% | -0.21 | -0.14 | -0.12 | -0.03 | 0.04 |
| Interest Expenses | 3.8% | 948,000,000 | 913,000,000 | - | - | - |
| Net Income | -82.4% | -2,353,000,000 | -1,290,000,000 | -1,054,000,000 | -615,000,000 | 417,000,000 |
| Net Income Margin | -85.1% | -0.16 | -0.09 | -0.07 | -0.04 | 0.03 |
| Free Cahsflow | 102.7% | 1,042,000,000 | 514,000,000 | 476,000,000 | 585,000,000 | 236,000,000 |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -0.6% | 44,006 | 44,252 | 45,932 | 47,059 | 47,666 |
| Current Assets | 5.2% | 12,051 | 11,453 | 12,164 | 12,451 | 12,573 |
| Cash Equivalents | 25.9% | 2,801 | 2,225 | 2,058 | 2,175 | 2,165 |
| Inventory | -0.7% | 3,833 | 3,859 | 4,049 | 4,012 | 3,818 |
| Net PPE | 3.1% | 5,739 | 5,568 | 5,740 | 5,932 | 5,982 |
| Goodwill | -4.3% | 17,633 | 18,433 | 18,837 | 19,986 | 20,040 |
| Liabilities | 1.7% | 35,315 | 34,734 | 36,103 | 36,799 | 36,422 |
| Current Liabilities | -0.6% | 11,469 | 11,534 | 10,996 | 11,613 | 11,027 |
| LT Debt, Current | -17.4% | 1,696 | 2,054 | 1,403 | - | - |
| Shareholder's Equity | -9.9% | 7,897 | 8,767 | 9,828 | 10,260 | 10,278 |
| Retained Earnings | -10.5% | -12,882 | -11,660 | -11,716 | -11,484 | -10,529 |
| Additional Paid-In Capital | 0.1% | 27,688 | 27,652 | 27,625 | 27,587 | 27,561 |
| Accumulated Depreciation | - | 5,241 | - | - | - | - |
| Shares Outstanding | 0.1% | 1,111 | 1,110 | 1,107 | - | - |
| Minority Interest | 5.7% | 794 | 751 | 791 | 916 | 966 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 48.2% | 1,590 | 1,073 | 1,059 | 1,154 | 798 |
| Share Based Compensation | 2.5% | 124 | 121 | 122 | 112 | 119 |
| Cashflow From Investing | -10.6% | 656 | 734 | 875 | 1,176 | 1,523 |
| Cashflow From Financing | -16.4% | -1,487 | -1,277 | -2,014 | -1,677 | -2,172 |
Risks for TEVA
What is the probability of a big loss on TEVA?
100%
Probability that Teva Pharmaceutical Industries stock will be more than 20% underwater in next one year
91.9%
Probability that Teva Pharmaceutical Industries stock will be more than 30% underwater in next one year.
43.9%
Probability that Teva Pharmaceutical Industries stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does TEVA drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Teva Pharmaceutical Industries was unfortunately bought at previous high price.
Drawdowns
Returns for TEVA
Cumulative Returns on TEVA
-13.2%
10-Year Cumulative Returns
-22.7%
7-Year Cumulative Returns
-13.9%
5-Year Cumulative Returns
1.1%
3-Year Cumulative Returns
What are the long-term rolling returns for TEVA?
FIve years rolling returns for Teva Pharmaceutical Industries.
Annualized Returns
Which funds bought or sold TEVA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -71.97 | -968,740 | 449,260 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 16.82 | 36,000 | 148,000 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -6.3 | 76,553 | 1,384,550 | -% |
2023-02-27 | Parallax Volatility Advisers, L.P. | reduced | -18.26 | -735,056 | 8,905,940 | 0.01% |
2023-02-24 | NATIXIS | new | - | 60,785 | 60,785 | -% |
2023-02-24 | National Pension Service | unchanged | - | 2,818 | 19,772 | -% |
2023-02-21 | MACQUARIE GROUP LTD | added | 17.69 | 97,437 | 393,437 | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -0.73 | 17,719 | 166,719 | -% |
2023-02-21 | DGS Capital Management, LLC | added | 39.61 | 50,932 | 139,089 | 0.09% |
2023-02-17 | TRUIST FINANCIAL CORP | reduced | -5.16 | 92,358 | 1,378,360 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Teva Pharmaceutical Industries News
Schedule 13G FIlings of Teva Pharmaceutical Industries
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | capital research global investors | 10.3% | 114,793,989 | SC 13G/A | |
| Feb 11, 2022 | capital research global investors | 12.0% | 132,350,750 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 11.9% | 130,140,247 | SC 13G/A | |
| Feb 03, 2021 | wellington management group llp | 0.03% | 310,793 | SC 13G/A | |
| Feb 14, 2020 | capital research global investors | 11.9% | 130,950,677 | SC 13G/A | |
| Feb 05, 2020 | franklin resources inc | 1.8% | 19,916,016 | SC 13G/A | |
| Jan 28, 2020 | wellington management group llp | 7.43% | 81,123,996 | SC 13G |
TEVA Fair Value
Teva Pharmaceutical Industries fair value in different scenarios
The table shows the Fair Value estimates for Teva Pharmaceutical Industries for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | - - | - - | - - | - - |
| Current Inflation | 5.96 -32.35% | 6.83 -22.47% | 9.92 12.60% | 12.06 36.89% | 13.99 58.80% |
| Very High Inflation | - - | - - | - - | - - | - - |
Historical Teva Pharmaceutical Industries Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Teva Pharmaceutical Industries
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 09, 2023 | 8-K | Current Report | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for TEVA
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-07 | Dethlefs Sven | sold | -547,440 | 9.4279 | -58,066 | evp, north america commercial |
2023-03-07 | Stark David Matthew | sold | -466,445 | 9.4279 | -49,475 | exec. vp chief legal officer |
2023-03-07 | Drape Eric | sold | -44,301 | 9.4279 | -4,699 | executive vp global operations |
2023-03-07 | Daniell Richard | sold | -509,173 | 9.4279 | -54,007 | exec. vp, european commercial |
2023-03-06 | Drape Eric | sold | -15,551 | 9.9309 | -1,566 | executive vp global operations |
2023-03-06 | Dethlefs Sven | sold | -192,213 | 9.9309 | -19,355 | evp, north america commercial |
2023-03-06 | Daniell Richard | sold | -178,776 | 9.9309 | -18,002 | exec. vp, european commercial |
2023-03-06 | Stark David Matthew | sold | -163,770 | 9.9309 | -16,491 | exec. vp chief legal officer |
2023-03-05 | Dethlefs Sven | acquired | - | - | 24,952 | evp, north america commercial |
2023-03-05 | Daniell Richard | acquired | - | - | 22,576 | exec. vp, european commercial |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Income Statement
2022-09-30Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
| Net revenues | $ 3,595 | $ 3,887 | $ 11,041 | $ 11,778 |
| Cost of sales | 1,926 | 2,093 | 5,839 | 6,234 |
| Gross profit | 1,669 | 1,794 | 5,203 | 5,544 |
| Research and development expenses | 175 | 222 | 628 | 723 |
| Selling and marketing expenses | 539 | 597 | 1,716 | 1,798 |
| General and administrative expenses | 283 | 291 | 892 | 822 |
| Intangible assets impairments | 24 | 21 | 223 | 295 |
| Goodwill impairment | 0 | 0 | 745 | 0 |
| Other assets impairments, restructuring and other items | 36 | 62 | 282 | 227 |
| Legal settlements and loss contingencies | 195 | 3 | 2,048 | 113 |
| Other income | (2) | (25) | (88) | (73) |
| Operating income (loss) | 419 | 623 | (1,244) | 1,638 |
| Financial expenses, net | 252 | 241 | 721 | 805 |
| Income (loss) before income taxes | 166 | 382 | (1,964) | 833 |
| Income taxes (benefit) | 107 | 76 | (792) | 235 |
| Share in (profits) losses of associated companies, net | 1 | 5 | (20) | (9) |
| Net income (loss) | 58 | 302 | (1,152) | 608 |
| Net income (loss) attributable to non-controlling interests | 3 | 11 | (21) | 32 |
| Net income (loss) attributable to Teva | $ 56 | $ 292 | $ (1,132) | $ 576 |
| Earnings (loss) per share attributable to ordinary shareholders: | ||||
| Basic | $ 0.05 | $ 0.26 | $ (1.02) | $ 0.52 |
| Diluted | $ 0.05 | $ 0.26 | $ (1.02) | $ 0.52 |
| Weighted average number of shares (in millions): | ||||
| Basic | 1,111 | 1,103 | 1,109 | 1,102 |
| Diluted | 1,119 | 1,109 | 1,109 | 1,109 |
TEVA Balance Sheet
2022-09-30Consolidated Balance Sheets - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 | ||
|---|---|---|---|---|
| Current assets: | ||||
| Cash and cash equivalents | $ 2,225 | $ 2,165 | ||
| Accounts receivables, net of allowance for credit losses of $94 million and $90 million as of September 30, 2022 and December 31, 2021 | 3,730 | 4,529 | ||
| Inventories | 3,859 | 3,818 | ||
| Prepaid expenses | 1,045 | 1,075 | ||
| Other current assets | 579 | 965 | ||
| Assets held for sale | 16 | 19 | ||
| Total current assets | 11,453 | 12,573 | ||
| Deferred income taxes | 1,546 | 596 | ||
| Other non-current assets | 438 | 515 | ||
| Property, plant and equipment, net | 5,568 | 5,982 | ||
| Operating lease right-of-use assets | 422 | 495 | ||
| Identifiable intangible assets, net | 6,393 | 7,466 | ||
| Goodwill | [1] | 18,433 | 20,040 | |
| Total assets | 44,252 | 47,666 | ||
| Current liabilities: | ||||
| Short-term debt | 2,769 | 1,426 | ||
| Sales reserves and allowances | 3,648 | 4,241 | ||
| Accounts payables | 1,635 | 1,686 | ||
| Employee-related obligations | 496 | 563 | ||
| Accrued expenses | 2,041 | 2,208 | ||
| Other current liabilities | 945 | 903 | ||
| Total current liabilities | 11,534 | 11,027 | ||
| Long-term liabilities: | ||||
| Deferred income taxes | 503 | 784 | ||
| Other taxes and long-term liabilities | 3,846 | 2,578 | ||
| Senior notes and loans | 18,497 | 21,617 | ||
| Operating lease liabilities | 354 | 416 | ||
| Total long-term liabilities | 23,200 | 25,395 | ||
| Commitments and contingencies, see note 10 | ||||
| Total liabilities | 34,734 | 36,422 | ||
| Teva shareholders' equity: | ||||
| Ordinary shares of NIS 0.10 par value per share; September 30, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively. | 57 | 57 | ||
| Additional paid-in capital | 27,652 | 27,561 | ||
| Accumulated deficit | (11,660) | (10,529) | ||
| Accumulated other comprehensive loss | (3,153) | (2,683) | ||
| Treasury shares as of September 30, 2022 and December 31, 2021: 106 million ordinary shares | (4,128) | (4,128) | ||
| Stockholders' equity attributable to Teva shareholders | 8,767 | 10,278 | ||
| Non-controlling interests | 751 | 966 | ||
| Total equity | 9,519 | 11,244 | ||
| Total liabilities and equity | $ 44,252 | $ 47,666 | ||
| ||||